Twin Capital Management Inc. Lowers Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Twin Capital Management Inc. lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,192 shares of the pharmaceutical company’s stock after selling 162 shares during the quarter. Twin Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $2,519,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Groesbeck Investment Management Corp NJ increased its holdings in shares of Vertex Pharmaceuticals by 20.4% during the 4th quarter. Groesbeck Investment Management Corp NJ now owns 1,773 shares of the pharmaceutical company’s stock worth $721,000 after buying an additional 300 shares during the last quarter. Federated Hermes Inc. boosted its stake in Vertex Pharmaceuticals by 6.5% in the 4th quarter. Federated Hermes Inc. now owns 205,361 shares of the pharmaceutical company’s stock worth $83,559,000 after purchasing an additional 12,542 shares during the period. Wright Investors Service Inc. bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at $578,000. Livforsakringsbolaget Skandia Omsesidigt grew its position in Vertex Pharmaceuticals by 1.2% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 22,065 shares of the pharmaceutical company’s stock worth $8,978,000 after purchasing an additional 258 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its position in shares of Vertex Pharmaceuticals by 1.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 36,987 shares of the pharmaceutical company’s stock valued at $15,049,000 after acquiring an additional 351 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $393.48 on Friday. The company has a market cap of $101.70 billion, a PE ratio of 28.33, a price-to-earnings-growth ratio of 1.85 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 52 week low of $316.43 and a 52 week high of $448.40. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. The firm’s 50-day simple moving average is $414.17 and its two-hundred day simple moving average is $396.74.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The firm had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the prior year, the firm posted $3.33 earnings per share. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Ratings Changes

VRTX has been the subject of a number of recent research reports. HC Wainwright boosted their price target on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the stock a “buy” rating in a research note on Thursday, April 11th. UBS Group lowered their price target on shares of Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research report on Wednesday. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and boosted their price target for the stock from $332.00 to $379.00 in a research report on Wednesday, January 24th. Finally, Sanford C. Bernstein lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, February 2nd. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.